|
|
|
|
|
|
Sponsored by: |
Latin American Cooperative Onco-Haematology Group - Peru |
Information provided by: | Latin American Cooperative Onco-Haematology Group - Peru |
ClinicalTrials.gov Identifier: | NCT00157274 |
The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.
Condition | Intervention | Phase |
Mycosis Fungoides Sezary Syndrome |
Drug: alemtuzumab |
Phase II |
MedlinePlus related topics: | Fungal Infections |
ChemIDplus related topics: | Alemtuzumab Campath |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome |
Estimated Enrollment: | 20 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | July 2008 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Julia M Huamani, MD | 511-2227020 | juliahuamaniz@yahoo.es |
Peru | |||||
Schering Peruana S.A. | Recruiting | ||||
Lima, Peru, 511 | |||||
Contact: Jesus A Arones, MD 99480078 alfredo_arones@hotmail.com |
Latin American Cooperative Onco-Haematology Group - Peru |
Principal Investigator: | Brady E Beltran, MD | LACOGH - PERU |
Study ID Numbers: | MF/SS |
First Received: | September 7, 2005 |
Last Updated: | April 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00157274 |
Health Authority: | Peru: General Directorate of Pharmaceuticals, Devices, and Drugs |
|
|
|
|
|